Evidence map›Paper›PMID 42145873›Full record

ArticleNeuro-oncology advances

A methylome-based score to predict survival after regorafenib in recurrent glioblastoma.

Silvia Chiesa, Evelina Miele, Sara Patrizi, Lucia Pedace, Ciro Mazzarella, Martina Offi, Antonella Martino, Maria Laura Falchetti, Giuliano Di Monaco, Rosellina Russo and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Silvia ChiesaDepartment of Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Evelina MieleDepartment of Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-4747-1032
Sara PatriziDepartment of Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Lucia PedaceDepartment of Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Ciro MazzarellaDepartment of Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Martina OffiDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Antonella MartinoDepartment of Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Maria Laura FalchettiInstitute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy.
Giuliano Di MonacoDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Rosellina RussoDepartment of Radiology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Flavia VinciarelliDepartment of Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Angela MastronuzziDepartment of Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-4408-2373
Simona GaudinoSchool of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy (M.O., G.D.M., S.G., L.L., M.A.G., F.L., A.O., M.G., Q.G.D.).
Maurizio MartiniDepartment of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', Section of Pathology, University of Messina, Messina, Italy.
Lucia Ricci-VitianiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Roberto PalliniDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-4611-8827
Liverana LaurettiDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0001-7997-1624
Maria Antonietta GambacortaDepartment of Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Franco LocatelliDepartment of Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-7976-3654
Alessandro OliviDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Marco GessiSchool of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy (M.O., G.D.M., S.G., L.L., M.A.G., F.L., A.O., M.G., Q.G.D.).
Quintino Giorgio D'AlessandrisDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-2953-9291

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Following the encouraging results of the REGOMA Phase 2 trial, regorafenib is increasingly used for the treatment of recurrent glioblastoma, IDH-wildtype. Identifying predictive factors for response to regorafenib is of paramount importance. DNA methylation profiling is considered the gold standard for diagnosing and classifying central nervous system tumors. We explored the predictive value of methylation profiling in recurrent glioblastoma patients treated with regorafenib. Methods: Thirty-three recurrent glioblastoma patients were enrolled in the study. DNA methylation profile was performed on paraffin-embedded tumor obtained at first surgery. Results: Median progression-free survival (PFS) and overall survival (OS) following regorafenib treatment were 3 and 7.5 months, respectively, aligning with findings from the REGOMA trial. Methylation classes RTK2 and mesenchymal were associated with an improved survival after regorafenib. Copy number variation analysis showed that imbalances in the p53-MDM2 and cyclin-Rb pathways negatively predict survival after regorafenib treatment. Multivariable analysis demonstrated that Conclusions: These findings highlight the potential of DNA methylation profiling in guiding therapeutic strategies and warrant further validation in clinical settings.

Indexed as

cell cycleDNA methylationglioblastomaprognostic scoreregorafenib

Identifiers

PMID42145873
PMCPMC13175173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.